A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
ConditionNon-Small-Cell Lung
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Stage I-III at initial NSCLC diagnosis
Aged ≥18 years at first diagnosis of NSCLC
NSCLC is not the primary cancer diagnosis
Patients with a recent history of other tumor or concurrent other tumor
Patients participating in interventional clinical trials at time of initial diagnosis
Patients with positive pregnancy status at the time of diagnosis